AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
Bristol-Myers upgraded at Leerink after AbbVie setback
Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...
pharmaphorum4d
Advantage BMS as AbbVie drug fails schizophrenia trials
If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Newsday15d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
In contrast to the weight gain seen with other schizophrenia drugs, people lost a few pounds while taking Cobenfy, made by Bristol Myers Squibb. Dr. John Krystal of Yale University has led ...
Too Old to Operate23h
FDA Approves Cobenfy for Adults With Schizophrenia
The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Business Insider4d
Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets
AbbVie’s two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing ... on TipRanks >> Read More on BMY: ...
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...
BioPharma Dive4d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Business Insider3d
Leerink upgrades Bristol to Outperform after AbbVie schizophrenia failure
Try Now>> See the top stocks recommended by analysts >> Read More on BMY: Bristol-Myers Squibb NewsMORE Related Stocks Indices Commodities Currencies Stocks ...